MS 049 is a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6 with IC 50 of 34 nM and 43 nM respectively.

UNC0642 is a selective inhibitor of G9a/GLP with IC50 of < 15 nM.

TP-064 is a potent and selective PRMT4 inhibitor. The in vitro activity of TP-064 includes inhibition of PRMT4 with IC50 < 10nM for methylation of H3 (1-25) and greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. In cellular assays, TP-064 inhibits the methylation of MED12 with IC50 = 43 nM.

UNC 0631 is a potent G9a inhibitor with IC50 value of 4 nM.

TC-E 5003 is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor.

EPZ020411 HCl is a potent and selective inhibitor of PRMT6 with IC50 of 10 nM, has > 10 fold selectivity for PRMT6 over PRMT1 and PRMT8.

HLCL-61 HCl is an inhibitor of PRMT5 that is used for the treatment of acute myeloid leukemia.

VTP-50469 is a novel, potent, selective, orally-available MeninMLL1 inhibitor, being effectively against MLL-rearranged and NPM1c+ leukemia, selectively killing cell lines with MLLrearrangements and NPM1c+ mutations.

GSK2807 Trifluoroacetate is a SMYD3 SAM-competitive inhibitor with Ki of 14 nM.

AZ505 is a potent and highly selective inhibitor of the oncogenic protein SMYD2 (IC50=0.12 μM) with potential anticancer activity, > 600 fold than SMYD3 (IC50> 83.3 μM), DOT1L (IC50> 83.3 μM), EZH2 (IC50> 83.3 μM).

WDR5-0103 is a selective antagonist of WD repeat-containing protein 5 (WDR5) with Kd of 450 nM.

MM-102 trifluoroacetate is a potent WDR5/mLL interaction inhibitor, achieves IC50 = 2.4 nM with an estimated Ki < 1 nM in WDR5 binding assay, which is > 200 times more potent than the ARA peptide.

OICR-9429 is an antagonist of the interaction of WDR5 with peptide regions of MLL and Histone 3.

A-196 is a potent and selective inhibitor of SUV420H1 and SUV420H2 with IC50s of 25 and 144 nM respectively.

UNC0224 is a selective inhibitor of G9a with IC50 of 15 nM.

MI-538 is a potent and selective MLL inhibitor (mixed lineage leukemia inhibitor).

PF-06726304 is a potent and selective EZH2 inhibitor with Ki value of 0.7 nM.

EZM 2302 is the first potent and selective inhibitor of CARM1 enzymatic activity with IC50 value of 6 nM.